International journal of surgery (London, England) · 2025
ANPEP as a potential mediator linking aspartame exposure to MAFLD: insights from network toxicology and multi-omics analyses.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xu Long, Zhang Chi, Xin Shengliang, Wang Wenjing, Fu Xinghuan, Hong Yuan, Qian Jiandan, Shi Wanwan, Li Xueying, Lin Yanjie, Yan Qiujing, Ma Jiaxi, Wang Yan, Wang Guiqiang
Аннотация
BACKGROUND: Aspartame (APM) is a widely consumed artificial sweetener that has recently been implicated in the pathogenesis of metabolic disorders. However, the molecular mechanisms linking APM to metabolic-associated fatty liver disease (MAFLD) remain poorly understood.
MATERIALS AND METHODS: This study employed a comprehensive analytical strategy, integrating network toxicology, molecular docking, molecular dynamics simulations, machine learning, bulk RNA sequencing and single-cell transcriptomics, Mendelian randomization, and histological validation, to systematically investigate APM-associated molecular targets and their potential role in MAFLD.
RESULTS: The ADMETlab3.0 prediction indicated that APM exhibits strong hepatotoxic potential. Network toxicology analysis identified 80 overlapping genes, among which ANPEP demonstrated the lowest binding energy to APM (-8.2 kcal/mol). Molecular dynamics simulations further confirmed the stability of this interaction. Bulk RNA-seq data revealed that ANPEP was significantly upregulated in MAFLD liver tissues (P < 0.001) and achieved robust diagnostic performance (AUC = 0.84, 95% CI: 0.69-1.00, P < 0.01). In mouse models, Anpep expression was significantly elevated (P = 0.005). Mendelian randomization analysis indicated that elevated ANPEP levels were significantly associated with a higher risk of MAFLD (OR = 1.069, 95% CI: 1.017-1.124, P = 0.008). Single-cell sequencing and immunofluorescence analyses consistently confirmed that ANPEP was predominantly localized in CD68⁺ myeloid cells and was markedly upregulated as early as the fibrotic initiation stage of MAFLD (P < 0.01).
CONCLUSION: ANPEP was identified as a potential target that links aspartame exposure to MAFLD, and was further associated with inflammation, lipid dysregulation, and fibrosis. These findings suggest that aspartame may not represent a safe strategy for weight management and could increase the risk of liver injury and MAFLD progression.
MATERIALS AND METHODS: This study employed a comprehensive analytical strategy, integrating network toxicology, molecular docking, molecular dynamics simulations, machine learning, bulk RNA sequencing and single-cell transcriptomics, Mendelian randomization, and histological validation, to systematically investigate APM-associated molecular targets and their potential role in MAFLD.
RESULTS: The ADMETlab3.0 prediction indicated that APM exhibits strong hepatotoxic potential. Network toxicology analysis identified 80 overlapping genes, among which ANPEP demonstrated the lowest binding energy to APM (-8.2 kcal/mol). Molecular dynamics simulations further confirmed the stability of this interaction. Bulk RNA-seq data revealed that ANPEP was significantly upregulated in MAFLD liver tissues (P < 0.001) and achieved robust diagnostic performance (AUC = 0.84, 95% CI: 0.69-1.00, P < 0.01). In mouse models, Anpep expression was significantly elevated (P = 0.005). Mendelian randomization analysis indicated that elevated ANPEP levels were significantly associated with a higher risk of MAFLD (OR = 1.069, 95% CI: 1.017-1.124, P = 0.008). Single-cell sequencing and immunofluorescence analyses consistently confirmed that ANPEP was predominantly localized in CD68⁺ myeloid cells and was markedly upregulated as early as the fibrotic initiation stage of MAFLD (P < 0.01).
CONCLUSION: ANPEP was identified as a potential target that links aspartame exposure to MAFLD, and was further associated with inflammation, lipid dysregulation, and fibrosis. These findings suggest that aspartame may not represent a safe strategy for weight management and could increase the risk of liver injury and MAFLD progression.